Oncology

Latest News

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Non-Invasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

September 25th 2014

Lung Infections May Hamper Efficacy of FDG-PET

A new retrospective study published in JAMA identified that tuberculosis and certain fungal infections in the lungs could hamper the efficient detection of lung cancer by FDG-PET imaging.

September 25th 2014

Treating Late-Stage Lung Cancer Not Cost-Effective: JTO Study

A prospective study published in The Journal of Thoracic Oncology found that the average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

September 24th 2014

Proton Radiation-Yea or Nay?

Controversy over the value of proton beam radiation continues to harass clinicians as the therapy emerges to be extremely useful in some, but not all, cancers. Additionally, payers sometimes refuse to cover treatment costs due to lack of evidence of efficacy.

September 24th 2014

NCI's New Approach With The Exceptional Responder Initiative

With the aim of understanding why some patients respond better to a particular drug, NCI has launched the Exceptional Responders Initiative, to generate molecular profiles of tumors that respond well to a particular treatment.

September 24th 2014

PAD2 Overexpression May Promote Skin Cancer

Research published this month in the journal Cancer Research, found that increased expression of the enzyme PAD2 in young mice could lead to skin tumors that could progress to invasive squamous cell carcinoma.

September 23rd 2014

Folowing AACR, ASCO Supports FDA's Guidance for LDTs

The ASCO statement corroborates the need for regulation of laboratory-developed tests, which are increasingly being used to guide personalized treatment in oncology as well as other therapeutic areas.

September 23rd 2014

Should We Pay Doctors Less for Colonoscopy?

Shivan J. Mehta, MD, MBA Scott Manaker, MD, PhD

Due to existing payment structures and practice patterns for colonoscopy, reducing endoscopist reimbursement may diminish access to and quality of colorectal cancer screening.

September 23rd 2014

Updated International Consensus Guidelines for Advanced Breast Cancer Published

The guidelines have been published in 2 journals: Breast and Annals of Oncology.

September 22nd 2014

Amgen's Blinatumomab Get's Breakthrough Status for ALL

The drug is the first in it's class - an antibody designed to engage 2 different targets simultaneously.

September 22nd 2014

New Graphene Biosensor to Detect Cancer Biomarkers

The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.

September 19th 2014

Gilead's Zydelig Receives EU Nod for CLL and FL

The approval in CLL is supported primarily by data from a randomized, placebo-controlled phase 3 trial in combination with rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The approval in FL, is supported by data from a single-arm phase 2 study (Study 101-09) of Zydelig monotherapy in 125 iNHL patients refractory to rituximab and alkylating-agent-containing chemotherapy.

September 19th 2014

Microbubbles: New Carrier for Chemotherapy Delivery

The study, conducted in pancreatic cancer patients in Norway, was presented at the annual meeting of the International Contrast Ultrasound Society in Chicago.

September 19th 2014

Recurrence of Breast Cancer Years After the Initial Tumor

Marj P. Zimmerman, MS, BSPharm Stanton R. Mehr

September 19th 2014

Cancer Trials Face a Shortage of Teen, Young Adult Enrollees

Surabhi Dangi-Garimella, PhD

September 19th 2014

Draft Statement: Evidence Connecting Diet to Colorectal, Breast Cancer Stronger Than Links to Lung, Prostate

Mary K. Caffrey

September 19th 2014

First PD-1 Inhibitor Approved for Melanoma

Surabhi Dangi-Garimella, PhD

September 19th 2014

AACR Seeks FDA Oversight on LDTs

Surabhi Dangi-Garimella, PhD

September 19th 2014

Immunotherapy Trials Offering Promise in Hard-to-Treat Pancreatic Cancer

Mary Caffrey

September 19th 2014

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development

Yair Benita, PhD Barbara Marino, PhD Aman Bhandari, PhD Roni Zeiger, MD Sachin H. Jain, MD, MBA

September 19th 2014

Moving Beyond BRCA Mutations in Familial Breast Cancer

Surabhi Dangi-Garimella, PhD

September 19th 2014

Breast Cancer Survivorship Programs: More Than a Treatment

Marj P. Zimmerman, MS, BSPharm Stanton R. Mehr

September 19th 2014

Avastin: First Molecule in Nearly a Decade for Metastatic Cervical Cancer

Surabhi Dangi-Garimella, PhD

September 19th 2014

FDA Oversight of Laboratory Developed Tests Essential for Patient Health and Safety

Rep. Louise M. Slaughter, MPH

September 19th 2014

Thyroid Cancer: Increased Incidence or Improved Diagnosis?

Sejal Saraiya, PharmD

September 19th 2014

Oncology Medical Home: Improved Quality and Cost of Care

Surabhi Dangi-Garimella, PhD

September 18th 2014

In The Literature: Ramucirumab Improves OS in Advanced Gastric Cancer Patients

The study, published in Lancet Oncology, found that ramucirumab significantly improved survival by over 2 months.

September 18th 2014

In The Literature: SNP Analysis Identifies New Prostate Cancer Susceptibility Loci

The study, published this week in Nature Genetics, is the product of an international collaboration that has identified 23 new loci that could lead to an increased risk of developing prostate cancer.

September 18th 2014

UK's NICE Wins Drug Price War With GSK

Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.

September 17th 2014

Study Questions Screening Policy on Mammographically-Dense Breasts in Women

The study, published in the Journal of Clinical Oncology, wants a policy revamp on screening guidelines for the women who fall in this category.

September 17th 2014

Gilead's Simtuzumab Fails in Phase 2

The antibody, an inhibitor of the enzyme lysyl oxidase-like-2, combined with gemcitabine, did not have a significant effect on progression-free survival compared to the placebo with gemcitabine arm, in pancreatic cancer patients.

...

151 152 153 154 155 156 157 158 159

...

185 >